Profil bibliographique

Stéphanie Ragot

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

218Publications signalées

4131Citations signalées

3Affiliations récentes

Institutions déclarées

Inserm Université de Poitiers Centre Hospitalier Universitaire de Poitiers

Domaines associés

Blood Pressure and Hypertension StudiesHeart Rate Variability and Autonomic ControlDiabetes Treatment and ManagementChronic Kidney Disease and DiabetesDiabetes Management and Research

Publications récentes

Accès ouvert 2026 preprintOpenAlex

Subcutaneous Isatuximab by On-Body-Injector plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma: ISASOCUT study

Arthur Bobin, Cyrille Touzeau, Nicolas Branche, A. Perrot et autres

0 citationsResearch Square

2026 articleOpenAlex

High-Flow or Standard Oxygen in Acute Hypoxemic Respiratory Failure

Jean-Pierre Frat, J. Quenot, Christophe Guitton, Rémi Coudroy et autres

12 citationsNew England Journal of Medicine

Accès ouvert 2025 articleOpenAlex

Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patients

Émilie Cayssials, Lucie Lefèvre, Amandine Decroos, Florence Jacomet et autres

1 citationCancer Immunology Immunotherapy

Accès ouvert 2025 articleOpenAlex

Association between respiratory-related cortical activation and weaning from mechanical ventilation: a physiological study

Christophe Rault, Arnaud W. Thille, Quentin Héraud, Stéphanie Ragot et autres

0 citationsCritical Care

Accès ouvert 2025 conference-abstractOpenAlex

Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05)

Arthur Bobin, Rick Zhang, Mony Morisse, Anaïs Schavgoulidze et autres

1 citationBlood

Accès ouvert 2025 conference-abstractOpenAlex

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia. a randomized national fi-LMC comparative trial of two therapeutic strategies.

Émilie Cayssials, Frédéric Bauduer, Viviane Dubruille, Valérie Coiteux et autres

0 citationsBlood

2025 articleOpenAlex

Rationale and design of the imaging for detection rate of cardiac transthyretin amyloidosis study (the IMPACT study)

Elsa Beard, Benjamin Alos, T. Rosenberg, Pierre‐Jean Saulnier et autres

0 citationsArchives of cardiovascular diseases

2025 articleOpenAlex

Characteristics of ventilator weaning in patients intubated for Guillain–Barré syndrome or myasthenia gravis: a nationwide multicenter study

Arnaud W. Thille, Constance Bayon, Clément Saccheri, Marie Labruyère et autres

3 citationsIntensive Care Medicine

Accès ouvert 2025 preprintOpenAlex

Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patients

Émilie Cayssials, Lucie Lefèvre, Amandine Decroos, Florence Jacomet et autres

0 citationsResearch Square

Accès ouvert 2025 articleOpenAlex

Optical Coherence Tomography to Better Assess Chronic Total Occlusion Percutaneous Intervention Results

Sébastien Levesque, Benjamin Faurie, Benoît Lattuca, Julien Lemoine et autres

1 citationJACC Advances

2025 articleOpenAlex

Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma: Results from ISASOCUT (IFM 2022–05)

Arthur Bobin, Anaïs Schavgoulidze, Stéphanie Ragot, Christophe Roul et autres

2 citationsClinical Lymphoma Myeloma & Leukemia

2025 articleOpenAlex

Development and Validation of a Surgical Performance Assessment Scale for Lung Lobectomy and Lymph Node Dissection

Clément Colombier, Géraldine Allain, Lisa Durocher, Stéphanie Ragot et autres

0 citationsEuropean Journal of Cardio-Thoracic Surgery

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.